I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer.
I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo.ch in 2018, I was a freelance journalist and a researcher on business and human rights.
Pharma’s obesity campaigns juggle awareness and advertising
This content was published on
Pharma giants are bankrolling obesity awareness campaigns, raising thorny questions about what constitutes drug advertising.
Truth or tale: can pharma companies set prices for new drugs as high as they want?
This content was published on
Debates over drug pricing have prompted Swissinfo readers to ask whether pharma companies can set prices for new drugs as high as they want.
How Switzerland bought rapid access to Covid vaccines
This content was published on
Switzerland released full Covid vaccine contracts, revealing the prices and terms it took for rapid access to vaccines during the pandemic.
Can Swiss pharma giant Roche reshape the obesity market?
This content was published on
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive market.
Drugmakers reassess Europe as Trump overhauls drug-pricing rules
This content was published on
President Trump's drug-pricing overhaul has triggered an earthquake in Europe as drugmakers scramble to protect their bottom lines.
This content was published on
In episode 6 of this season's Swiss Connection science podcast, we look at the role of relationships and perceptions in longevity.
Science podcast: the story behind the ‘longevity pill’ rapamycin
This content was published on
In episode 5 of this season's Swiss Connection science podcast, we talk about the discovery of TOR and its potential for longevity.
From London to Lausanne: how Isomorphic Labs is rewriting drug discovery
This content was published on
Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to "solve all diseases" with AI.
Science podcast: Can gender diversity create better medicine?
This content was published on
In episode 3 of this season's Swiss Connection science podcast we look at the role of sex and gender in drug development.
What lies ahead for Switzerland: an economic outlook for 2026
This content was published on
in 2026, the Swiss economy will face downward pressure from weaker domestic demand and ongoing uncertainty related to US import tariffs.
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
